dabigatran has been researched along with 2019 Novel Coronavirus Disease in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 10 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Everington, T; Husted, M; McKeague, L; Sly, D | 1 |
| Alkhameys, S; Barrett, R | 1 |
| Ha, N; Hess, R; Mouland, E; Renner, E; Sutter-Long, D | 1 |
| Alexander, GC; Andersen, KM; Boyce, RD; Gomez-Lumbreras, A; Kocis, PT; Kravchenko, OV; Leonard, CE; Malone, DC; Mehta, H; Tan, M; Villa Zapata, L | 1 |
| Charushin, VN; Fedorova, OV; Gaidukova, KA; Gorbunov, EB; Ignatenko, NK; Ishmetova, RI; Kucheryavenko, AF; Ovchinnikova, IG; Rasputin, NA; Rusinov, GL; Sadykhov, GAO; Sirotenko, VS; Spasov, AA; Verbitskiy, EV | 1 |
| Betti, M; Danzi, GB; Dellanoce, C; Giorgi-Pierfranceschi, M; Morandini, R; Palareti, G; Pan, A; Paoletti, O; Prandoni, P; Tala, M; Testa, S | 1 |
| Eikelboom, JW; Eriksson, N; Ezekowitz, MD; Granger, CB; Hijazi, Z; Lindbäck, J; Lopes, RD; Oldgren, J; Siegbahn, A; Wallentin, L; Yusuf, S | 1 |
| Chukhliaev, PV; Garbuzov, AA; Khavkina, DA; Ploskireva, AA; Ruzhentsova, TA | 1 |
| D'Elia, E; Di Marco, F; Falanga, A; Gori, M; Grosu, A; Iorio, A; Lorini, FL; Senni, M | 1 |
| Buenen, AG; Maas, ML; Sinkeldam, M; Verdonschot, M; Wever, PC | 1 |
1 trial(s) available for dabigatran and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation.
Topics: Aged; Angiotensin-Converting Enzyme 2; Antithrombins; Atrial Fibrillation; Betacoronavirus; Biomarkers; Cohort Studies; Coronavirus Infections; COVID-19; Dabigatran; Female; Humans; Male; Middle Aged; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Pyrazoles; Pyridones; Risk Factors; SARS-CoV-2; Stroke; Warfarin | 2020 |
9 other study(ies) available for dabigatran and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
"I just didn't want to trust it at all": Atrial fibrillation patient's treatment experience of rivaroxaban and warfarin.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; COVID-19; Dabigatran; Humans; Rivaroxaban; Stroke; Trust; Warfarin | 2022 |
Impact of the COVID-19 pandemic on England's national prescriptions of oral vitamin K antagonist (VKA) and direct-acting oral anticoagulants (DOACs): an interrupted time series analysis (January 2019-February 2021).
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; COVID-19; Dabigatran; England; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Interrupted Time Series Analysis; Pandemics; Prescriptions; Pyridones; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2022 |
Proportion of Patients on Warfarin Therapy Who Are Eligible for Conversion to a Direct Oral Anticoagulant in the Setting of COVID-19.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; COVID-19; Cross-Sectional Studies; Dabigatran; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2023 |
Drug-drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case-control study in the National COVID Cohort Collaborative (N3C).
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Case-Control Studies; COVID-19; COVID-19 Drug Treatment; Dabigatran; Dexamethasone; Drug Interactions; Factor Xa Inhibitors; Humans; Pyridones; Retrospective Studies; Rivaroxaban | 2022 |
Novel Substituted Azoloazines with Anticoagulant Activity.
Topics: Anticoagulants; Antiviral Agents; COVID-19; Dabigatran; Humans; Hypoglycemic Agents | 2023 |
Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Dabigatran; Darunavir; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Italy; Lopinavir; Male; Pandemics; Patient Safety; Pneumonia, Viral; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Ritonavir; SARS-CoV-2; Severity of Illness Index; Thiazoles | 2020 |
[Effect of anticoagulant therapy on the course of COVID-19 in comorbid patients].
Topics: Acetylcysteine; Aged; Aged, 80 and over; Anticoagulants; Antiviral Agents; Atrial Fibrillation; Azithromycin; Cohort Studies; Comorbidity; Coronary Disease; COVID-19; COVID-19 Drug Treatment; Dabigatran; Disseminated Intravascular Coagulation; Female; Humans; Hypertension; Indoles; Interferon alpha-2; Intracranial Arteriosclerosis; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; SARS-CoV-2; Severity of Illness Index; Survival Analysis | 2021 |
An unexpected case of recurrence of pulmonary embolism in a patient recovered from COVID19 in full regimen dose of direct oral anticoagulant drug.
Topics: Administration, Oral; Anticoagulants; COVID-19; Dabigatran; Drug Therapy, Combination; Heparin; Humans; Male; Middle Aged; Pulmonary Embolism; Recurrence; Warfarin | 2021 |
Prior use of anticoagulation is associated with a better survival in COVID-19.
Topics: Administration, Oral; Anticoagulants; COVID-19; Dabigatran; Fibrinolytic Agents; Humans; Netherlands; Survival Rate; Vitamin K | 2021 |